Pricing and reimbursement of pharmaceuticals in Belgium

PharmacoEconomics

Volumn 11, Issue 3, 1997, Pages 203-209

  Annemans, Lieven ^a,c   Crott, Ralph ^b   De Clerq, Henri ^c   Huybrechts, Michel ^d   Peys, Frank ^e   Robays, Hugo ^f   Steens, Ingrid ^c   Vanschoubroek, Kathleen ^g   Winderickx, Peter ^h  

^a BRI International   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d Astra Pharmaceuticals Belgium   (Belgium)

^e Belg Institute of Health Economics   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Amgen NV   (Belgium)

^h Dworp   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BELGIUM; DRUG COST; HEALTH CARE COST; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY;

EID: 0031046280     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711030-00001     Document Type: Short Survey

References (20)

1. De geneesmiddelenindustrie in België. Algemene Vereniging van de Geneesmiddelenindustrie, Oct 1995
2. Facts and Figures, Cost Development of Pharmaceutical Aid. Stichting Farmaceutische Kengetallen, 1996
3. Compendium 1994. Belgian Institute for Health Economics, Dec 1994
4. Annual Report 1994. INAMI, 1995
5. Reuben BJ, Burstall ML. Pricing and reimbursement regulation in Europe: the industry perspective. Drug Inf J 1995; 29: 273-83
6. Soumerai SB, Ross-Degnan D, Avorn J et al. Effects of medicaid drug-payment limits on admissions to hospitals and nursing homes. N Engl J Med 1991; 325: 1072-9
7. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331: 650-5
8. Redwood H. Public policy trends in drug pricing and reimbursement in the European Community. Pharmacoeconomics 1994; 6 Suppl. 1: 3-10
9. Abbott TA. Price regulation in the pharmaceutical industry: prescription or placebo? J Health Econ 1995; 14: 551-65
10. Smith J. Patterns of prescribing London: Office of Health Economics, 1991
11. Rutten FFH. Economic appraisal and drugs policy. Paper presented at the symposium: "Economic evaluations in health care". Leuven, 1995 Apr 8
12. Avouac B. Successfully submitting health economic analyses to the transparency commission. Paper presented at PharmEcon Europe 95; 1995 Jul 5-6: Paris
13. Wilson R, Rowan MS, Henderson J. Introduction to the Canadian Medical Association's decision making framework. Can Med Assoc J 1995; 152: 1063-6
14. Clemens K, Garrison Jr LP, Jones A. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1993; 4: 315-22
15. Johannesson M. Economic evaluation of drugs and its potential uses in policy making. Pharmacoeconomics 1995; 8 (3): 190-8
16. Hutton J. Cost-benefit analysis in health care decision-making. Health Econ 1992; 1: 213-6
17. A proposal for methodological guidelines for economic evaluation of pharmaceuticals - Belgium. Belgian Society for Pharmacoepidemiology, Nov 1995
18. Beutels Ph, Tormans G, Van Damme P, et al. Algemene vaccinatie tegen Hepatitis B in Vlaanderen, kosten-effectief? Tijdschr Soc Gezondheidszorg 1996; 74: 272-81
19. Closon MC, Crott R, Even-Adin D. Drug use in relation to clinical activities as an instrument for prospective drug budgeting. Pharmacoeconomics 1996; 9: 246-63
20. Nonneman W, Van Doorslaer E. The role of the sickness funds in the Belgian Health Care Market. Soc Sci Med 1994; 39 (10): 1483-95